Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianantonio Rosti

Showing results (111-120 of 153) with videos related to

Pageof 16
Sort By:
Blood|October 3, 2009
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WPNicoletta Testoni, Giulia Marzocchi, Simona Luatti, et al.
Cancer|March 3, 2018
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinibFabio Efficace, Fausto Castagnetti, Bruno Martino, et al.
Haematologica|July 30, 2016
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patientsFausto Castagnetti, Massimo Breccia, Gabriele Gugliotta, et al.
Haematologica|June 27, 2015
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Blood|June 25, 2013
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainSimona Soverini, Caterina De Benedittis, K Machova Polakova, et al.
Blood|June 14, 2012
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysisSimona Luatti, Fausto Castagnetti, Giulia Marzocchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trialJane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.
Blood|July 14, 2011
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general populationFabio Efficace, Michele Baccarani, Massimo Breccia, et al.
Blood|May 17, 2013
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemiaDomenico Russo, Giovanni Martinelli, Michele Malagola, et al.
Blood|August 18, 2021
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trialJorge Cortes, Jane Apperley, Elza Lomaia, et al.
Pageof 16

Showing results (111-120 of 153) with videos related to

Sort By:
Pageof 16
Blood|October 3, 2009
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WPNicoletta Testoni, Giulia Marzocchi, Simona Luatti, et al.
Cancer|March 3, 2018
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinibFabio Efficace, Fausto Castagnetti, Bruno Martino, et al.
Haematologica|July 30, 2016
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patientsFausto Castagnetti, Massimo Breccia, Gabriele Gugliotta, et al.
Haematologica|June 27, 2015
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Blood|June 25, 2013
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainSimona Soverini, Caterina De Benedittis, K Machova Polakova, et al.
Blood|June 14, 2012
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysisSimona Luatti, Fausto Castagnetti, Giulia Marzocchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trialJane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.
Blood|July 14, 2011
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general populationFabio Efficace, Michele Baccarani, Massimo Breccia, et al.
Blood|May 17, 2013
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemiaDomenico Russo, Giovanni Martinelli, Michele Malagola, et al.
Blood|August 18, 2021
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trialJorge Cortes, Jane Apperley, Elza Lomaia, et al.
Pageof 16